36 patients of group A are younger than 65 years old; 48 patients of group B are between 65 and 80; 75 patients of group C are older than 80.
delay of this group was remarkable, whereas it was not noticeable in groups B and C. Immunosuppressed cases with complications like DM and low PS cases tended to increase with age. as statin-user, NsLLA-user and those without LLA (LLA-free). Patients were observed for TB development (the primary outcome) from T2DM diagnosis date until treatment crossover or December 2013. The secondary outcomes included shingles and liver abscess. Cox regression was used, and statin-user and NsLLA-user were time-dependent variables.
Results: During a 240,782 person-years of follow-up, TB incidences were 115, 182, and 279 per 100,000 person-years in statin-user (n = 17,696), NsLLA-user (n = 5,327), and LLA-free group (n = 22,316), respectively. In a multivariate analysis, statin-users had a 34% reduced risk of TB compared with NsLLA-users (aHR, 0.66; 95% CI, 0.44-0.99) after adjustment for age, sex, income levels, rural residence, metformin dose and comorbidities. This association was further confirmed in an age-, sex-, calendar-year-matched subcohort. In contrast, the incidence of shingles was higher in statin-user than in NsLLA-user and LLA-free groups (957, 690, and 812 per 100,000 person-years). The statin-users had a 23% increased risk of shingles compared with NsLLA-users (aHR, 1.23; 95% CI,1.01-1.50). Notably, the risk of TB and shingles were not statistically different between NsLLA-user and LLA-free groups. There was no association between statin-user and the risk of liver abscess.
Conclusion: T2DM patients treated with statin had a decreased risk of TB but an increased risk of shingles compared to those with NsLLA. 
Methods:
The study was performed at a South Korean tertiary referral centre between January 2011 and June 2017. In total, 740 patients with IBD who underwent LTBI screening tests and were followed-up for ≥1 year after TNF inhibitor treatment initiation were enrolled. LTBI was detected on the basis of tuberculin skin test results, interferon-gamma release assay results, chest X-ray findings, and previous tuberculosis treatment history. The patients were classified into LTBI (n = 84) or non-LTBI (n = 656) group. The risk of developing tuberculosis in each group was assessed on the basis of standardized incidence ratio (SIR) and 95% confidence interval (CI) for active tuberculosis.
Results: Mean patient age was 33.1 years, and patients with Crohn's disease were predominant (80.7%). Within 1 year after the initiation of TNF inhibitor treatment, 1 patient in the LTBI group (1/84; 1.2%) and 7 patients in the non-LTBI group (7/656; 1.1%) developed active tuberculosis. The overall 1-year incidence of tuberculosis among the patients was significantly higher than that among the general population (SIR 14.0, 95% CI 7.0-28.0), and SIR was not affected by LTBI status (LTBI group: 14.5, 95% CI 2.0-102.6; non-LTBI group: 14.0, 95% CI 6.7-29.4).
Conclusion:
Patients with IBD undergoing TNF inhibitor treatment showed a higher 1-year incidence of tuberculosis than the general population irrespective of LTBI status. 
